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Abstract
We and others have recently reported an association between amyotrophic lateral sclerosis (ALS) and single nucleotide polymorphisms
on chromosome 9p21 in several populations. Here we show that the associated haplotype is the same in all populations and that several
families previously shown to have genetic linkage to this region also share this haplotype. The most parsimonious explanation of these data
are that there is a single founder for this form of disease.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease affecting motor neurons characterized by
rapidly progressive weakness and ultimately death from
respiratory failure typically within 3 years of symptom
onset. Understanding the genetic etiology of the disease has
been a focus for the ALS research community, as each new
gene provides fundamental insights into the pathogenesis of
motor neuron degeneration, as well as accelerating disease
modeling and the design and testing of targeted therapeu-
tics.
Using a genome-wide association study (GWAs) ap-
proach, we recently reported that a locus on chromosome
9p21 accounted for  40% of familial ALS and nearly
-fourth of all ALS cases in a sample of 405 Finnish
atients (Laaksovirta et al., 2010). This association signal
ad previously been reported by van Es et al. (2009) as
howing association with ALS and a meta-analysis amongst
any studies showed that this was indeed the major signal
or this disease (Shatunov et al., 2010). Similarly, a recent
WAs for frontotemporal dementia (FTD) with TDP-43
athology had also identified this locus (Van Deerlin et al.,
010).
Linkage analysis of kindreds affected with multiple cases
f ALS, FTD, and FTD-ALS with type 2 TDP-43 pathology
ad suggested there was an important locus for the disease
n chromosome 9p (Boxer et al., 2011; Morita et al., 2006;
earson et al., 2011; Vance et al., 2006) but it had not been
lear whether the linkage and association signals related to
single locus or whether the different studies were report-
ng the same alleles at that locus.
The analysis in the Finnish population had narrowed the
ssociation signal to a 232 kb block of linkage disequilib-
ium, and allowed the identification of a haplotype that
ncreased risk of disease by over 20-fold. Despite consid-
rable efforts in our laboratories and others the underlying
ausative variant and deleterious mutation has not yet been
dentified.
Here, we examine the prevalence of the Finnish risk
aplotype in other European populations to determine its
eographical distribution and to analyze the possibility that
t represents a founder mutation. We then tested this hap-
otype in ALS and FTD families with evidence of linkage to
his region to determine if the same haplotype is responsible
or both ALS and FTD. In the 4 families for which we had
ccess to primary genetic data, the haplotype was consistent
ith the Finnish one.
. Methods
We analyzed GWAs data obtained for ALS patients and
eurologically normal controls in 5 populations in which we
ave access to the raw genotype data. These are the Finnish
ataset (Laaksovirta et al., 2010), the Irish dataset (Cronin et
l., 2008), the UK dataset (Shatunov et al., 2010), the USataset (Schymick et al., 2007), and the Italian dataset (Chiò
t al., 2009). All cohorts had been genotyped using Illumina
San Diego, CA, USA) single nucleotide polymorphism
SNP) arrays. Standard quality control procedures were
pplied to each dataset prior to combining summary statis-
ics for meta-analysis. In brief, samples were excluded if
hey had call rates less than 95%, phenotype-genotype gen-
er discordance, demonstrated cryptic relatedness (defined
s pi_hat greater than 12.5%, effectively removing all first or
econd degree relatives), or outliers from the populations with
uropean ancestry (defined as  3 standard deviations away
rom the combined European Caucasians [HapMap 3 release 3,
010 (International HapMap 3 Consortium, 2010)] population
ean in components vectors 1 and 2, using PLINK Multidi-
ensional scaling plot). SNPs were excluded if they had a
inor allele frequency (MAF)  0.01, Hardy-Weinberg equi-
ibrium p-value  106 in controls, missing by haplotype p
value  104, or evidence of nonrandom missingness in
ases versus controls (p value 104). Meta-analyses were
erformed with METAL (Willer et al., 2010) for fixed-
ffect and PLINK (Purcell et al., 2007) for random-effects
odel. Haplotype analysis was performed using Haplo-
iew 4.2 to evaluate the possibility of population-based
ifferences (Barrett et al., 2005). Additional statistical
nalyses were performed using R (version 2.11.1, R De-
elopment Core Team, 2010). Subsequently, we tested
amilies where phased genotype data generated on vari-
us SNP chips was available to establish the relationship
etween the 9p21 susceptibility region and the Mendelian
inkage regions.
. Results
We performed a meta-analysis of 5 ALS genome-wide
ssociation studies involving a total of 2017 cases and 3639
ontrols drawn from the 5 datasets. As expected, meta-
nalysis confirmed the presence of previously identified
ocus on chromosome 9p21 (most significantly with im-
uted SNP  rs2477521, p value  4.51  1011 based on
fixed-effect model with heterogeneity p value of 1.5 
104, and an overall p value  0.00876 based on more
onservative random-effects model). Heterogeneity esti-
ates suggested significant variation in the effect size from
ifferent populations, with the Italian population being a
requent outlier. Secondary analysis without the Italian co-
ort yielded a markedly more robust p value for the same
NP (p value for rs2477521 under the fixed effect model 
.24  1013; rs10967973 with p value under the random
ffects model 1.55 1010). This suggests that the effect
at this SNP differs markedly when comparing between
populations of Northern and Southern European ancestry.
The original risk haplotype identified within the Finnish
ALS population consisted of 42 SNPs stretching over a 232
kb region of chromosome 9p21 (Laaksovirta et al., 2010).
This block of linkage disequilibrium was shorter in the
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kb region), as would be expected in an outbred European
population compared with the genetically homogeneous
Finnish population (Shifman and Darvasi, 2001). Of
these 24 SNPs, only 21 had been genotyped in all 5
populations. Furthermore, the most centromeric SNP of
these 21 (rs1444533) did not show convincing associa-
tion with disease in either the UK or Irish population.
This SNP was therefore dropped from subsequent anal-
ysis, leaving a 20 SNP risk haplotype common to all
Northern European ancestry groups in this meta-analysis.
Thus, we restricted subsequent analyses to the region
chr9: 27467874-27579657 (NCBI36/hg18) between SNP
rs1444533 and rs696826.
This 20 SNP haplotype was associated with disease in
Finland, was less significantly associated in the UK and US
populations (Table 1); this haplotype had only a trend to-
ward association in the Irish population (p  0.17) and
showed no evidence of association at all in the Italian
population. The 20 SNP haplotype is consistent with the
association recently reported for both FTD (Van Deerlin et
al., 2010; Rollinson et al., 2011; see Table 2) and for ALS
in a Dutch study although the incompleteness of the pub-
lished data in these studies precludes a formal comparison.
Analysis of SNP chip data in 4 families with FTD or
FTD-ALS (Boxer et al., 2011; Pearson et al., 2011; Seelaar
et al., 2011; Traynor and Hardy, unpublished) in which
linkage data was generated using SNP chips (Table 2)
revealed that a similar disease haplotype was found in all
patients with the exception of the most distal SNP
(rs2477518) in the family reported by Seelaar et al. (2011).
These data suggest that the same conserved chromosome
9p21 20 SNP risk haplotype underlies both ALS and FTD in
multiple populations and that a proportion at least of the
families showing genetic linkage to the region also share
Table 1
Twenty SNP haplotype frequencies in cases and controls
Population Number
(case:control)
Frequency p
Case Control
Finland 405:497 0.23 0.098 3.169E-14
Ireland 221:211 0.147 0.116 0.1716
Italy 500:247 0.129 0.149 0.3183*
UK 620:1890 0.182 0.135 9.17E-05
USA 271:794 0.145 0.111 0.0443
Haplotype frequencies in cases and controls and the p-value (2) for the
ominal significance of the difference between them. The 20 SNPs are:
s1822723, rs4879515, rs868856, rs7046653, rs1977661, rs903603,
s10812610, rs2814707, rs3849942, rs12349820, rs10122902, rs10757665,
s1565948, rs774359, rs2282241, rs1948522, rs1982915, rs2453556,
s702231, and rs696826.
ey: SNP, single nucleotide polymorphism.
* In contrast to the other populations, the Italian cases have a marginally
decreased frequency of the risk haplotype.this rather short haplotypic region.4. Discussion
These results are consistent with a single haplotype being
associated with ALS, FTD, and FTD-ALS in most of the
populations studied with the strength of the association
being strongest in populations from Northern Europe that
exhibit some estimated degree of Scandinavian ancestry and
progressively weaker as one moves south and the contribu-
tion of this ancestral background is reduced. This interpre-
tation is also consistent with the data from van Es et al.
(2009) who first identified this association and showed a
stronger association in a Swedish population than in the
others included in their analysis (note that this analysis
partially overlaps with our analysis reported here). This
haplotype has the structure shown in Table 2 and extends
over 140 kb and 3 genes MOBKL2B, C9orf72, and IFNK.
Although this is the simplest explanation it is worth con-
sidering what other explanations would be consistent with
the data. One such explanation is that the haplotype carries
a premutation (such as an expanded repeat) which is pre-
disposed to give rise independently to pathogenic alleles of
differing penetrances.
The observations described above have several implica-
tions. First, if only a single founding haplotype bears the
mutation this suggests that all, or at least the majority of
individuals, with the disease possess the same pathogenic
variant. Second, the lack of pathogenic coding mutations in
the known genes within this locus suggests that the muta-
tion(s) is of an unusual type involving something other than
a simple missense or nonsense change. Possibilities would
include inversions similar to the MAPT H2 haplotype, or
the inclusion of cryptic exons or the exclusion of exons
caused by variants distant from splice sites. Third, it seems
that the same associated haplotype is found in both FTD and
ALS. In this latter regard, it is interesting that, whereas a
founder mutation of the MAPT gene largely explains the
Manchester focus of FTD (Pickering-Brown et al., 2002)
the well documented Lund focus of FTD in Sweden remains
unexplained. Fourth, our data are consistent with the same
haplotype being responsible for the disease in families
showing linkage to this region suggesting they harbor the
same pathogenic mutation: certainly this is the case in those
families to which we have access. By explicitly publishing
this haplotype, our data will enable those who have access
to other families to assess whether this same haplotype is
present in their families. It remains unclear as to why the
apparent penetrance of the haplotype appears to be so vari-
able. It could be that this reflects ascertainment bias, or that
there have been subsequent additional variants accrued onto
this ancient haplotype, or it could be that there is another
epistatic locus elsewhere in the genome which influences
penetrance as Gijselinck and colleagues have suggested
(2010).
Clearly, the identification of this locus remains a ma-
jor goal of ALS and FTD research. Our data suggest that
Table 2
The 24-SNP Finnish haplotype compared with 20 SNP haplotype and data from other populations, families, and publications
SNP Position
on ch9
This study Consensus
20 SNP
haplotype
Previous association studies Data from families
Finnish Irish US UK Italian Van Es et al.
(2009)
Van Deerlin
et al. (2010)
Rollinson
et al.
(2011)
Boxer et al.
(2011)
Seelaar et al.
(2011)
Pearson et al.
(2011)
US number
3 (Traynor
and Hardy,
unpublished)
rs1444533 27467874 A A A A A Aa — — — A A T A
rs1822723 27468052 C C C C C C — — — C C — —
rs4879515 27472235 T T T T T T — — — T T T T
rs895023 27473959 T — T T T — — — T T T T T
rs868856 27479251 T T T T T T — — T T T T T
rs7046653 27480967 A A A A A A — — — A A A A
rs2440622 27485418 A — A A A — — — A A A A A
rs1977661 27492986 C C C C C C — — C C C C C
rs903603 27519316 C C C C C C — — C C C C C
rs10812610 27523984 C C C C C C — — C C C C C
rs2814707 27526397 A A A A A A A A A A — A A
rs3849942 27533281 A A A A A A A A A A — A A
rs12349820 27543876 T T — T — — — — — T T T T
rs10122902 27546780 G G G G G G — — G G G G G
rs10757665 27547919 T T T T T T — — T T — T T
rs1565948 27549733 G G G G G G — — G G — G G
rs774359 27551049 C C C C C C — C — C — C C
rs2282241 27562255 G G G G G G — — G G G G G
rs1948522 27565785 C C C C C C — — C C C C C
rs1982915 27569560 G G G G G G — — — G G G G
rs7868845 27574530 T/C
rs2453556 27576162 G G G G G G — — — G G G G
rs702231 27578731 A A A A A A — — — A A A A
rs696826 27579657 G G G G G G — — — G G G G
rs2477518 27589746 T T T T/C T — — — T C T T
Haplotype deduced directly from array genotyping (this study) or haplotype given or deduced from previous publications, or haplotype derived from linkage analysis of families we have analyzed. Imputed
SNP genotypes are not given. [—] indicates genotype not assessed or not clear because of ambiguous phase. The family US number 3 has not been published but has a phenotype consistent with other families
with this phenotype and a lod score of 1.2 with chromosome 9 markers. Note the discrepant results for Pearson et al. rs1444533 (centromeric) and Boxer et al. rs2477518 (telomeric) which suggest definitive
flanking SNPs for the locus. SNPs included in the haplotype analysis are in bold.
Key: ch9, chromosome 9; SNP, single nucleotide polymorphism.
a rs1444533 was dropped from the 20 SNP haplotype analysis.
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sequencing of the locus and of all the transcripts ema-
nating from it.
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